Quest's profits make it Barron's favourite:
This article was originally published in Clinica
Quest Diagnostics is predicting that the doubling of its first-quarter profits, to $36 million, will lead to a full year earnings growth of at least 50%. Its position was noted by US financial weekly Barron's, which awarded Quest first place in its annual survey of the top 500 companies in the US. Quest says that it has been able to reduce costs from its 1999 acquisition of SmithKline Beecham Laboratories and is deriving higher margins from gene-based testing.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.